MET is also amplified in 5% of newly diagnosed lung adenocarcinomas (Cappuzzo et al, 2009; Kong‐Beltran et al, 2006; Tsuta et al, 2012), and cMet inhibitors are effective in patients with gene copy numbers > 5 (Salgia, 2017). Here, MET is linked to lung adenocarcinoma.